Literature DB >> 20939765

The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.

Yuping Liu1, Miaoqin She, Zhicong Wu, Renke Dai.   

Abstract

Human uridine-5'-diphosphoglucuronosyltransferases (UGTs) are the major phase II metabolizing enzymes. In the present study, five human UGTs (UGT1A1, 1A4, 1A6, 2B7, and 2B10) were individually expressed and used to examine the inhibition IC(50) values of 20 selective substrates and inhibitors of major cytochromes P450 (CYPs). The inhibition kinetics of UGT1A1 was also analyzed. The results showed that some compounds like α-naphthoflavone, paclitaxel, midazolam, cyclosporine A, and ketoconazole displayed strong inhibitions on UGT activities with their IC(50) values in a range of 4.1-26 µM. Especially, the IC(50) values were 4.1 ± 0.8 µM for ketoconazole in inhibiting UGT1A1-mediated β-estradiol-3-glucuronidation, and 4.9 ± 0.3 µM for paclitaxel towards UGT1A4-mediated midazolam-N-glucuronidation. Additionally, the IC(50) values of bupropion, tolbutamide, and testosterone in inhibiting UGT-mediated metabolisms were similar with the K(m) values of respective CYPs. Some kinetic behaviours of UGTs were following Michaelis-Menten kinetics, while some were not.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20939765     DOI: 10.3109/14756366.2010.518965

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  6 in total

1.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

2.  Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Authors:  Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 3.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

4.  Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.

Authors:  N Marsousi; Y Daali; S Rudaz; L Almond; H Humphries; J Desmeules; C F Samer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-12-17

5.  Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Authors:  Andrea E Steuer; Corina Schmidhauser; Eva H Tingelhoff; Yasmin Schmid; Anna Rickli; Thomas Kraemer; Matthias E Liechti
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

6.  Absorption, Metabolic Stability, and Pharmacokinetics of Ginger Phytochemicals.

Authors:  Rao Mukkavilli; Chunhua Yang; Reenu Singh Tanwar; Ahmed Ghareeb; Latika Luthra; Ritu Aneja
Journal:  Molecules       Date:  2017-03-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.